Exelixis (NASDAQ:EXEL) Price Target Raised to $47.00

Exelixis (NASDAQ:EXEL) had its price objective upped by Stifel Nicolaus from $44.00 to $47.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Stifel Nicolaus’ price target indicates a potential downside of 0.98% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Truist Financial raised Exelixis to a “strong-buy” rating in a report on Monday, April 27th. Barclays boosted their price target on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a research note on Monday, April 20th. Morgan Stanley boosted their price target on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Finally, TD Cowen restated a “buy” rating on shares of Exelixis in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus target price of $47.44.

Exelixis Trading Up 6.9%

Shares of NASDAQ:EXEL traded up $3.05 during trading on Wednesday, hitting $47.47. 2,752,299 shares of the company were exchanged, compared to its average volume of 2,710,657. The stock has a market cap of $12.06 billion, a price-to-earnings ratio of 17.18, a P/E/G ratio of 0.99 and a beta of 0.38. Exelixis has a fifty-two week low of $33.76 and a fifty-two week high of $49.62. The firm has a fifty day moving average price of $43.32 and a two-hundred day moving average price of $42.86.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.55 EPS. As a group, research analysts predict that Exelixis will post 3.07 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Dana Aftab sold 47,918 shares of the company’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the completion of the sale, the executive vice president directly owned 616,106 shares in the company, valued at approximately $27,416,717. This represents a 7.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Brenda Hefti sold 18,669 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total value of $821,622.69. Following the sale, the senior vice president owned 96,512 shares of the company’s stock, valued at approximately $4,247,493.12. The trade was a 16.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 362,849 shares of company stock worth $15,917,463 over the last three months. 2.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Exelixis

A number of institutional investors have recently modified their holdings of the stock. Gallacher Capital Management LLC lifted its position in shares of Exelixis by 35.2% during the 1st quarter. Gallacher Capital Management LLC now owns 17,013 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 4,434 shares during the period. Financiere des Professionnels Fonds d investissement inc. lifted its position in shares of Exelixis by 28.4% during the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 37,008 shares of the biotechnology company’s stock valued at $1,587,000 after acquiring an additional 8,192 shares during the period. Bessemer Group Inc. lifted its position in shares of Exelixis by 36.8% during the 1st quarter. Bessemer Group Inc. now owns 1,972 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 530 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Exelixis by 23.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,707,715 shares of the biotechnology company’s stock valued at $75,208,000 after acquiring an additional 323,895 shares during the period. Finally, Westover Capital Advisors LLC lifted its position in shares of Exelixis by 3.0% during the 1st quarter. Westover Capital Advisors LLC now owns 89,009 shares of the biotechnology company’s stock valued at $3,818,000 after acquiring an additional 2,582 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q1 EPS beat and margin improvement — Exelixis reported $0.87 GAAP EPS vs. $0.75 consensus and showed strong profitability metrics, which supports near‑term earnings visibility. Exelixis (EXEL) Tops Q1 Earnings Estimates
• Positive Sentiment: $750M buyback announced and management commentary — Company disclosed a $750M repurchase authorization tied to buyback‑driven EPS accretion, a clear driver of shareholder value and a reason for the stock’s upward move. Exelixis outlines December PDUFA timeline for ZANZA CRC filing while adding $750M buyback
• Positive Sentiment: Analysts lift targets and reiterate buys — Several firms raised price targets (e.g., TD Cowen to $55 and Morgan Stanley to $50) or reiterated bullish views citing Cabo durability and buyback EPS support, which underpins the rally. Exelixis Price Target Raised to $55 Price Target Raised to $50 (Morgan Stanley)
• Neutral Sentiment: Revenue roughly flat to expectations — Q1 revenue of ~$610.8M was essentially in line with consensus (slight miss in some reports), and FY2026 revenue guidance was reiterated/updated to about $2.5–2.6B, leaving room for debate about growth pacing vs. street models. Exelixis (EXEL) Tops Q1 Earnings Estimates (Yahoo)
• Neutral Sentiment: Conference call and transcripts available — Management discussed Cabo durability, Zanzalintinib regulatory timelines (December PDUFA for CRC filing referenced) and execution priorities; useful for investors wanting detail but not an immediate price catalyst. Earnings Call Transcript Earnings Call Summary
• Negative Sentiment: Cabometyx sales momentum mixed — Some reports note Cabometyx sales lagged estimates, and analysts flag competitive pressure and pipeline uncertainty as risks to sustained top‑line growth. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
• Negative Sentiment: Mixed analyst stance — Some firms (e.g., Wells Fargo) raised price targets but kept neutral/equal‑weight ratings, signaling potential downside from current levels and that enthusiasm is not unanimous. Benzinga (Wells Fargo note)

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.